



ECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE

A. MARTINEZ OREA¹, <u>P. TORRANO-BELMONTE</u>¹, M.D. NÁJERA PÉREZ¹, L. FRUCTUOSO GONZALEZ¹, J.A. GUTIERREZ SÁNCHEZ¹, M. HERNÁNDEZ SÁNCHEZ¹, M. GUILLÉN DÍAZ¹.

¹HOSPITAL MORALES MESEGUER, PHARMACY, MURCIA, SPAIN.

Background

Clinical trials (CTs) offer a chance to treat patients with new or current therapies, seeking to find novel drugs and combinations and expand treatment options for diseases. According to current legislation (RD1090/2015), sponsors are required to provide all investigational medication, except for certain exceptions.

Aim and objectives

The objective of this study is to estimate the cost savings generated by medications used in clinical trials for multiple myeloma (MM) at a tertiary-level hospital.

Materials and methods



Retrospective, single-center observational study



2018-2022



Exclusion criteria:

✓ CTs that didn't enroll patients during the study period

✓ CTs that didn't dispense medication.



Main study variable:


✓ Avoided medication cost over five years.




Secondary variables:


✓ Average cost saved per CT.

✓ Average cost saved per patient.




Results








123







67 patients were recruited.

Direct cost saved over five years

€2.920.608,28

€224.662,17/CT

Conclusion and relevance

The development of CTs in the study center generated significant economic savings in MM treatment. This cost provided by sponsors should be reinvested in the creation of well-equipped clinical trial units.